FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to novel peptides, their pharmaceutical compositions and application in method of reducing intraocular pressure and method of treating or preventing ophthalmological diseases, mediated by natriuretic peptides or proteins.
EFFECT: obtaining compositions for intraocular pressure reduction.
8 cl, 5 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW NPR-B AGONISTS | 2010 |
|
RU2636738C2 |
| VERSIONS OF C-TYPE NATRIURETIC PEPTIDE | 2010 |
|
RU2573911C2 |
| COMPOSITION OF DERMAL MEDICATION FOR EXTERNAL APPLICATION | 2010 |
|
RU2572694C2 |
| CONTROLLED RELEASE COMBINATION THERAPY WITH CNP AGONISTS | 2017 |
|
RU2768747C2 |
| THERAPEUTIC AGENT FOR TREATING RHINITIS | 2010 |
|
RU2502519C2 |
| DIPEPTIDE LINKED MEDICINAL AGENTS | 2009 |
|
RU2578591C2 |
| USE OF OPTIONS OF NATRIURETIC PEPTIDE OF TYPE C FOR TREATMENT OF OSTEOARTHRITIS | 2016 |
|
RU2759679C2 |
| APPLICATION OF C-TYPE NATRIURETIC PEPTIDE VARIANTS FOR THE TREATMENT OF SKELETAL DYSPLASIA | 2016 |
|
RU2794515C2 |
| APPLICATION OF VARIANTS OF NATRIURETIC PEPTIDE OF C-TYPE FOR TREATMENT OF SKELETAL DYSPLASIA | 2016 |
|
RU2728567C2 |
| GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | 2011 |
|
RU2604067C2 |
